143 related articles for article (PubMed ID: 10100921)
1. Biological activity of GLP-1-analogues with N-terminal modifications.
Siegel EG; Gallwitz B; Scharf G; Mentlein R; Morys-Wortmann C; Fölsch UR; Schrezenmeir J; Drescher K; Schmidt WE
Regul Pept; 1999 Feb; 79(2-3):93-102. PubMed ID: 10100921
[TBL] [Abstract][Full Text] [Related]
2. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro.
Gallwitz B; Ropeter T; Morys-Wortmann C; Mentlein R; Siegel EG; Schmidt WE
Regul Pept; 2000 Jan; 86(1-3):103-11. PubMed ID: 10672909
[TBL] [Abstract][Full Text] [Related]
3. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
4. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
8. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
9. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
10. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Xiao Q; Giguere J; Parisien M; Jeng W; St-Pierre SA; Brubaker PL; Wheeler MB
Biochemistry; 2001 Mar; 40(9):2860-9. PubMed ID: 11258897
[TBL] [Abstract][Full Text] [Related]
11. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
13. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
[TBL] [Abstract][Full Text] [Related]
15. Structure/activity characterization of glucagon-like peptide-1.
Gallwitz B; Witt M; Paetzold G; Morys-Wortmann C; Zimmermann B; Eckart K; Fölsch UR; Schmidt WE
Eur J Biochem; 1994 Nov; 225(3):1151-6. PubMed ID: 7957206
[TBL] [Abstract][Full Text] [Related]
16. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
[TBL] [Abstract][Full Text] [Related]
17. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity.
John H; Maronde E; Forssmann WG; Meyer M; Adermann K
Eur J Med Res; 2008 Feb; 13(2):73-8. PubMed ID: 18424366
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
19. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
20. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer TJ; McIntosh CH; Pederson RA
Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]